Date:April 12, 2019 - 9:00 AM to April 12, 2019 - 3:00 PM
To listen to this discussion, visit https://nih.webex.com/nih/onstage/g.php?MTID=ec32f727d4423c79ab62e1aac9…
Hosted by the National Institute on Alcohol Abuse and Alcoholism (NIAAA).
Chair - Ian Colrain
9:00 - 9:15 Introductions
9:15 - 9:40 Alcohol success stories.
A good place to start is to review some of the progress that has already be made. The opening panel highlights some successes that have already been made, thus setting the stage for where we need to go next. Primary discussants: Dave Gustafson (ACHESS), Kathleen Carroll (CBT4CBT), Reid Hester (Checkup and Choices)
9:40 – 10:05 Technical pitfalls: IRB, data security, ethics, consequences.
One thing we need to be aware of, right at the outset, is that the privacy and security issues are much sharper in remote sensor research than in most other research approaches. We need to take stock of the ethical issues in this field and keep them in mind throughout the rest of the day’s discussions. Primary discussants: Dana Wolff-Hughes, Wendy Nilsen, Fred Muench
10:05 – 10:30 Clinical perspectives.
The ultimate test of mobile technologies is whether they will improve our ability to treat alcohol use disorders. How can emerging technologies be incorporated into clinical practice, and how valuable as clinical aids might they become? Primary discussants: Sarah Lord, Rajita Sinha, Fred Muench, Alexis Kuerbis
10:30 – 10:50 Break
10:50 – 11:15 Applications for epidemiology and prevention research.
Two other potential applications are the use of mobile devices for collecting research data about drinking behavior and for delivering prevention interventions. In addition to the clinical promise, we need to assess the potential of these devices for epidemiological and prevention research. Primary discussants: Ken Sher, Brian Suffoletto, Denis McCarthy
11:15 – 11:40 Lessons from sister fields.
What can alcohol researchers learn from the experience so far in using mobile technology to treat or prevent other disease conditions? What do we need to be aware of about progress made in other disease research? Primary discussants: Ben Marlin, Dana Wolff-Hughes, Wendy Nilsen
11:40 – 12:40 Lunch
12:40 – 1:05 Wearables I commercial community.
NIAAA made a very public investment in promoting biosensor development. We issued a challenge grant competition to develop a trans-dermal alcohol sensor. This led to the development of the BACtrack Skyn and ION. Did we go far enough, and what remains to be done to put usable tools into the hands of researchers? Primary discussants: Keith Nothacker, Bob Lansdorp
1:05 – 1:30 Wearables II research community.
In addition to those developed under the NIAAA grand challenge, what other research grade and consumer wearables show promise for alcohol research? What are the challenges associated with their validation? How accepted are commercial wearables by the research community? Primary discussants: Susan Luczak, Nancy Barnett, Kathy Jung, Jen Buckman, Massimiliano de Zambotti
1:30 – 1:55 FDA approval.
What will the FDA requirements be for technologies developed in this area? At present, it is not entirely clear whether those requirements will be mandatory or not. We need to assess the current status of this issue and think about the pros and cons of the options on the table. Primary discussants: Geoff White, Reid Hester. Still working on FDA participation
1:55 – 2:20 Going to market.
What needs to happen for these products to become available on the commercial market? Do researchers and/or the Institute need to get involved in this process or is it best left to commercial businesses? What kinds of collaborations would be most helpful in moving development along? Primary discussants: Kathleen Carroll, Reid Hester, Sarah Lord
2:20 - 2:30 Break
2:30 – 3:00 Wrap-up
NIH Webex - Listen Only Discussion